A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (<i>scyllo</i>-Inositol) in Young Adults with Down Syndrome without Dementia - Concepedia

Concepedia

Publication | Open Access

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (<i>scyllo</i>-Inositol) in Young Adults with Down Syndrome without Dementia

DOI Full Paper Access

37

Citations

20

References

2017

Year

Michael S. Rafii, Brian G. Skotko, Mary Ellen McDonough, Margaret B. Pulsifer, Casey L. Evans, Eric Doran, Gabriela Muranevici, Patrick Kesslak, Susan Abushakra, Ira T. Lott

Journal of Alzheimer s Disease

Abstract

Overall, treatment of adults with DS with ELND005 at both doses was well tolerated, achieved measurable blood levels and demonstrated no safety findings. Further studies will be needed to test efficacy.

References

	Year	Citations
The Neuropsychiatric Inventory Jeffrey L. Cummings, Michael S. Mega, Kevin F. Gray, Neurology	1994	7.4K
Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome K. E. Wisniewski, Henryk M. Wı́sniewski, G. Y. Wen Annals of Neurology	1985	1.2K
Inositol Stereoisomers Stabilize an Oligomeric Aggregate of Alzheimer Amyloid β Peptide and Inhibit Aβ-induced Toxicity JoAnne McLaurin, Rivka Golomb, Anna Jurewicz, Journal of Biological Chemistry Molecular BiologyPeptide ScienceSynaptic SignalingCellular PhysiologyInhibit Aβ-induced Toxicity	2000	264
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease Stephen Salloway, Reisa A. Sperling, Ron Keren, Neurology	2011	252
Amygdala and hippocampal volumes in children with Down syndrome: A high-resolution MRI study Joseph D. Pinter, Wendy E. Brown, Stéphan Eliez, Neurology NeuropsychologyBrain FunctionDevelopmental Cognitive NeuroscienceHippocampal VolumesNeuropsychiatry	2001	197
Development and validation of the Arizona Cognitive Test Battery for Down syndrome Jamie O. Edgin, Gina Mason, Melissa J. Allman, Journal of Neurodevelopmental Disorders NeuropsychologyDisabilityCognitive Testing BatteryCognitive RehabilitationSocial Sciences	2010	182
Orally available compound prevents deficits in memory caused by the Alzheimer amyloid‐β oligomers Matthew Townsend, James Cleary, Tapan Mehta, Annals of Neurology	2006	164
High Brain <i>myo</i>-Inositol Levels in the Predementia Phase of Alzheimer’s Disease in Adults With Down’s Syndrome: A <sup>1</sup>H MRS Study Wei Huang, Gene E. Alexander, Eileen Daly, American Journal of Psychiatry	1999	148
The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21 Gerard T. Berry, John Mallee, H. Moo Kwon, Genomics	1995	132
Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology Daniela Fenili, Mary E. Brown, Rebecca Rappaport, Journal of Molecular Medicine MedicinePathologyAd-like PathologySclerodermaPharmacology	2007	128

Page 1